Toggle navigation
Login
Toggle navigation
JavaScript is disabled for your browser. Some features of this site may not work without it.
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.
QMRO Home
Barts Cancer Institute
Centre for Molecular Oncology
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.
QMRO Home
Barts Cancer Institute
Centre for Molecular Oncology
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.
Browse
All of QMRO
Communities & Collections
By Issue Date
Authors
Titles
Subjects
This Collection
By Issue Date
Authors
Titles
Subjects
Administrators only
Login
Statistics
Most Popular Items
Statistics by Country
Most Popular Authors